CUMBERLAND PHARMACEUTICALS INC (CPIX)

SEC fundamentals · as filed in 10-Q FY2026, period ended Jun 30, 2026 · updated Oct 7, 2026

Verified against EDGAR
Total Assets
$62.9M
Stockholders' Equity
$17.4M
Cash & Equivalents
$3.9M
Long-Term Debt
—

as filed in 10-Q FY2026, period ended Jun 30, 2026 · View filings on EDGAR ↗

In its 10-Q for the period ended Jun 30, 2026, CUMBERLAND PHARMACEUTICALS INC reported revenue of $8.8M, net income of -$4.3M, and total assets of $62.9M. Every figure below is taken directly from CUMBERLAND PHARMACEUTICALS INC's SEC filings: each links to the source document on EDGAR.

Revenue trend

Revenue · FY2016–FY2025 · as reported

$44.5M$18.3M-$8.0M
FY2016FY2019FY2022FY2025
Revenue$44.5MNet income-$2.8M
FY2016 revenue
$33.0M
FY2025 revenue
$44.5M

Revenue and net income by fiscal year

As reported in each year’s annual filing · USD

Fiscal yearRevenueNet income
FY2025$44.5M-$2.8M
FY2024$37.9M-$6.5M
FY2023$39.6M-$6.3M
FY2022$42.0M-$5.6M
FY2021$36.0M-$3.5M
FY2020$37.4M-$3.3M
FY2019$34.4M-$3.5M
FY2018$29.3M-$7.0M
FY2017$41.2M-$8.0M
FY2016$33.0M-$944,683

Recent SEC filings

Filed by the registrant · newest first · insider forms and holder schedules not included

FormFiledSource
8-KOct 26, 2026on EDGAR ↗
8-KOct 23, 2026on EDGAR ↗
8-KAug 28, 2026on EDGAR ↗
10-QAug 7, 2026on EDGAR ↗
8-KAug 4, 2026on EDGAR ↗
8-KJul 13, 2026on EDGAR ↗
8-KJul 1, 2026on EDGAR ↗
8-KJun 25, 2026on EDGAR ↗
10-QMay 8, 2026on EDGAR ↗
8-KMay 5, 2026on EDGAR ↗

All filings on EDGAR ↗

Balance Sheet

as of Jun 30, 2026 · 10-Q

Total Assets$62.9Msource ↗
Stockholders’ Equity$17.4Msource ↗
Cash & Equivalents$3.9Msource ↗
Long-Term Debt—source ↗

Income Statement

10-Q (quarterly) · period ended Jun 30, 2026

Revenue$8.8Msource ↗
Net Income-$4.3Msource ↗
Operating Income-$3.2Msource ↗
Gross Profit—source ↗
Cost of Revenue—source ↗
R&D Expense$772,162source ↗

Per Share & Cash Flow

10-Q (quarterly) · period ended Jun 30, 2026

EPS (diluted)$-0.29source ↗
EPS (basic)$-0.29source ↗
Shares Outstanding15.0Msource ↗
Cash from Operations$168,740source ↗
Cash from Financing-$5.4Msource ↗
Cash from Investing-$1.9Msource ↗

Restatement history

Point-in-time

16 of 506 annual fact-keys were materially restated between filings: what CUMBERLAND PHARMACEUTICALS INC first reported differed from what it later filed. We keep every vintage of every annual figure, each keyed to its EDGAR accession.

See each original-vs-restated value, and query any company as of any past date, with the point-in-time API.

Deeper fundamentals

A free API key reaches CPIX’s revenue, margin and free-cash-flow trajectory (newest 3 fiscal years) and its leverage, liquidity and return ratios (newest 4 quarters). Analyst extends those to up to 20 years and 20 quarters, and adds the Piotroski F-score and accruals quality score. As-of fundamentals at any past date are on Free too, up to 10 lookups a day; Analyst removes that cap and adds the original-vs-restated detail, across the whole SEC universe.

Programmatic access

Everything on this page is served by the Distill API and by the MCP server at mcp.distillmarkets.com. A free key is issued at sign-up with no card; the full reference is in the docs.

These fundamentals, as filed
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/CPIX

MCP tool: get_sec_fundamentals ticker=CPIX

The same figures as they were known on any past date
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/CPIX/as-of/YYYY-MM-DD

MCP tool: get_asof_fundamentals ticker=CPIX as_of=YYYY-MM-DD

Fiscal-year trajectory: revenue, margins, free cash flow
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/CPIX/history

MCP tool: get_fundamentals_history ticker=CPIX

Leverage, liquidity, margin and return ratios
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/financial-health/CPIX

MCP tool: get_financial_health ticker=CPIX

Not investment advice. Figures are shown as filed with the SEC; see the EDGAR source links for the original documents. Data may lag the latest filing.